Alpha- Antitrypsin Deficiency – Pipeline Review, H2 2018: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Alpha- Antitrypsin Deficiency, also called as AAT is a genetic disease that causes serious lung diseases that leads to difficulty in breathing. The disease might further spread to weaken the liver which would lead to jaundice. No cure has been discovered so far but with effective treatment, AAT can be kept in control without causing major respiratory difficulties. This disease is causes due to inability of the liver to produce a protein called Alpha- 1 antitrypsin in adequate quantities. Without this protein, irritants can easily attack the lungs at a faster rate. Symptoms are hard to be detected until in 20s or 30s when they slowly start surfacing. For a few people, AAT can lead to chronic bronchitis and even chronic pulmonary obstructive disease. Many affected with AAT often carry inhalers to ease their breathing just like in asthma. However, no two cases of AAT are alike. Neutrophil elastase (NE) is capable of degrading a variety of structural proteins of the extracellular matrix. Excessive NE activity have been detected in various lung diseases, including bronchitis, pulmonary obstructive diseases. Endogenous human NE is mostly neutralised by AAT. Congenital deficiency of AAT leads to emphysema which can be treated with therapeutic AAT. Of recently, many synthetic and recombinant elastase inhibitors have been identified and are in the stage of development for clinical and preclinical purposes. Pipeline Review is an online portal that provides R&D new and online shop for reports about research & development in the biopharmaceutical industry. Ken Research’s Alpha- Antitrypsin Deficiency – Pipeline Review, H2 2018 gives a snapshot of the therapeutic landscape of the disorder. The report covers therapeutic reviews based on their companies and research institutions based on their information derived from industry- specific sources. It provides descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The companies involved in therapeutic development in Alpha- Antitrypsin Deficiency are Adverum Biotechnologies Inc, Alnylam Pharmaceuticals Inc, Applied Genetic Technologies Corp, Arrowhead Pharmaceuticals Inc, AstraZeneca Plc, Carolus Therapeutics Inc, Editas Medicine Inc, Grifols SA, Inhibrx LP, Intellia Therapeutics Inc, International Stem Cell Corp, Kamada Ltd, Octapharma AG, OncBioMune Pharmaceuticals Inc, PlantForm Corp, Promethera Biosciences SA, ProMetic Life Sciences Inc, rEVO Biologics Inc, Santhera Pharmaceuticals Holding AG, Therapure Biopharma Inc and Z Factor Ltd. The report will help in procuring important information on competitors and their analysis to formulate R&D strategies to develop tactical initiatives in the target demographic. For more information, click on the link below: https://www.kenresearch.com/healthcare/pharmaceuticals/alpha-antitrypsin-deficiency/154209-91.html Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91-9015378249 Post Views: 2 Tags: Alpha Antitrypsin Deficiency Market, Alpha Antitrypsin Deficiency Market Analysis, Alpha Antitrypsin Deficiency Market Forecast, Alpha Antitrypsin Deficiency Market Outlook, Alpha Antitrypsin Deficiency Market Research Report, Alpha Antitrypsin Deficiency Market Revenue, Alpha Antitrypsin Deficiency Market Segmentation, Alpha Antitrypsin Deficiency Market Size, Alpha Antitrypsin Deficiency Market Trends, Alpha Antitrypsin Deficiency Pipeline Review